AGRX - Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying Opportunity
Agile Therapeutics (AGRX) recently announced that the FDA decided to extend Twirla’s PDUFA goal date from November 16th to February 16th, 2020. This extension comes about a week after Twirla received a positive vote in support of approval from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee “BRUDAC.” Following the press release, the share price was nearly cut in half, which I believe is an opportunity for investors who have been waiting for an entry point or are looking to add to their position.
I will provide some background information